On August 1, 2026, the latest data released by Hong Kong Exchanges and Clearing Limited (HKEX) showed that the Hong Kong IPO market experienced a strong recovery in the first half of 2026, with total fundraising exceeding HK$150 billion, a year-on-year increase of more than 40%, re-entering the top three global new stock fundraising markets. The news attracted widespread market attention, marking the Hong Kong market's renewed appeal to quality companies after a deep adjustment.
H1 IPO Market Recovers Notably, Financing Scale Surges
According to HKEX disclosures, from January to June 2026, nearly 50 new stocks were listed on the Hong Kong market, raising a total of approximately HK$158 billion, an increase of about 41% from HK$112 billion in the same period of 2025. Among them, the second quarter performed particularly well, with quarterly fundraising exceeding HK$90 billion, setting the strongest quarterly record in nearly five years. Accounting firms such as Deloitte and KPMG previously forecast that full-year Hong Kong IPO fundraising could exceed HK$300 billion, returning to the peak level of 2021.
By industry, new economy companies became the most core driving force. AI, new energy vehicle supply chain, biopharmaceutical, and consumer technology companies together contributed more than 60% of total fundraising. Many unicorn companies chose Hong Kong as their preferred listing venue, including a leading mainland autonomous driving solution provider and a biotech company focused on innovative drug development, which raised approximately HK$12 billion and HK$8 billion respectively, becoming the two largest IPOs in the first half.
Policy Reforms and Liquidity Improvement Jointly Lay Foundation for Recovery
The Hong Kong IPO recovery was not accidental, but the result of multiple favorable factors. First, HKEX has continued to advance listing system reforms in recent years, including lowering the listing thresholds for specialist technology companies, introducing the SPAC mechanism, and optimizing the GEM-to-Main Board transfer process, significantly enhancing the market's inclusiveness for growth enterprises. In the first quarter of 2026, HKEX announced further relaxation of listing requirements for pre-revenue biotech companies, allowing them to use mid-stage clinical data of core products as a basis for valuation, a move that directly catalyzed a wave of biopharmaceutical companies listing in Hong Kong.
Second, the improvement in global liquidity provided favorable conditions for new stock issuance. In 2026, the Fed entered a rate-cutting cycle, market risk appetite rose significantly, and capital accelerated its flow into Asian markets with relatively reasonable valuations. As an important hub connecting mainland China with global capital, Hong Kong naturally became a beneficiary. The CEO of HKEX said at the interim results press conference: "Hong Kong's fundraising function is being fully repaired. We not only see mainland enterprises continuing to come to Hong Kong, but also more and more international enterprises regarding Hong Kong as the preferred listing venue in Asia."
New Stocks Perform Well, Wealth Effect Attracts Investors
Besides the expansion of financing scale, the overall performance of new stocks after listing in the first half was also extremely encouraging. According to statistics, among the nearly 50 new stocks in the first half, about 35 closed higher on their debut day, with an average first-day gain of 18%, far higher than the 7% in the same period of 2025. Among them, several hot new stocks saw oversubscription multiples of thousands of times. For example, a new energy upstream materials company received more than 5,000 times oversubscription for its public offering portion, freezing over HK$600 billion in funds, making it one of the most popular IPOs among retail investors in Hong Kong history.
The strong wealth effect spurred more investors to participate in IPO subscriptions. Participation by Stock Connect investors in new stock subscriptions also increased significantly, with the amount of funds subscribed through Stock Connect up more than three times year-on-year. A veteran Hong Kong stock analyst pointed out: "The current Hong Kong IPO market has formed a virtuous cycle: companies are willing to list because they can obtain high valuations; investors are willing to subscribe because of the strong wealth effect; this in turn attracts more quality companies, further activating the market."
Second Half Outlook: Large Projects Ready to Launch, Full-Year Fundraising Expected
Looking ahead to the second half of 2026, the momentum of the Hong Kong IPO market is expected to continue. According to the list of listing applications disclosed by HKEX, more than 80 companies are currently waiting to be listed, including several long-awaited mega projects. Market sources say a leading domestic chip design company has passed the hearing and is expected to list in the third quarter, with fundraising possibly exceeding HK$20 billion; another internationally renowned logistics technology company also plans to list in Hong Kong by the end of the year, which is expected to push the full-year total fundraising even higher.
There are also rumors that HKEX is actively engaging with companies in Southeast Asia and the Middle East to attract more overseas companies to dual-list in Hong Kong. With the deepening of the "Belt and Road" capital markets, Hong Kong's reach as an international financing platform is expanding from mainland China to a broader region. Many investment banks believe that Hong Kong's full-year IPO fundraising in 2026 could reach HK$300 billion to HK$350 billion, setting the highest record since 2011.
Investor Strategy Recommendations: Subscribe Rationally, Focus on Fundamentals
Facing the possible IPO feast in the second half, investors should participate actively while remaining rational. Experts suggest that investors should avoid blindly chasing hot topics and instead focus on the core competitiveness and valuation reasonableness of companies. Specific strategies include:
- Prioritize industry leaders: Against a backdrop of improving industry conditions, leading enterprises often possess stronger risk resistance and growth certainty, and are more likely to gain long-term capital support after listing.
- Watch the cornerstone investor lineup: Participation by well-known international institutions or industry giants usually reflects professional investors' recognition of a company, serving as a value reference.
- Assess the match between valuation and growth: Some new stocks may be priced on the high side; investors should compare with comparable companies and average industry P/E ratios to determine whether there is a margin of safety.
- Diversify subscriptions and control positions: IPO subscription is not a guaranteed profit, especially for small-cap companies with high volatility. It is recommended to treat IPO subscription as a small part of asset allocation and avoid over-concentration.
Overall, the recovery of the Hong Kong IPO market reflects the vitality and resilience of Hong Kong's financial market. With the sustained recovery of the mainland Chinese economy and the reallocation of global capital, Hong Kong stocks are gradually emerging from the downturn and moving toward a new stage of high-quality development. For investors, this is both an era full of opportunities and one that demands stronger professional discernment and risk control awareness. Whether the Hong Kong market can continue to attract global quality enterprises and capital in the future deserves continued attention.
Data sources for this article: public information compiled from HKEX, Deloitte, KPMG, etc. For reference only and does not constitute investment advice.
